{"id":"braf","name":"BRAF","symbol":"BRAF","route":"/targets/braf/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1097","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000157764","uniprot":"https://www.uniprot.org/uniprotkb/P15056/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P15056","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL5145","open-targets":"https://platform.opentargets.org/target/ENSG00000157764","civic":"https://civicdb.org/genes/673/summary","oncokb":"https://www.oncokb.org/gene/BRAF","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=BRAF","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=BRAF","depmap":"https://depmap.org/portal/gene/BRAF?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000157764-BRAF","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/673","omim":"https://www.omim.org/entry/164757"}],"products":[{"id":"binimetinib","name":"Binimetinib","status":"approved","modality":"Small-molecule kinase inhibitor (MEK1/2)","route":"/drugs/binimetinib/"},{"id":"cobimetinib","name":"Cobimetinib","status":"approved","modality":"Small-molecule kinase inhibitor (MEK1/2)","route":"/drugs/cobimetinib/"},{"id":"dabrafenib","name":"Dabrafenib","status":"approved","modality":"Small-molecule BRAF kinase inhibitor","route":"/drugs/dabrafenib/"},{"id":"dabrafenib-trametinib","name":"Dabrafenib + trametinib","status":"approved","modality":"Small-molecule kinase inhibitors (BRAF + MEK)","route":"/drugs/dabrafenib-trametinib/"},{"id":"donafenib","name":"Donafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (deuterated sorafenib)","route":"/drugs/donafenib/"},{"id":"encorafenib","name":"Encorafenib","status":"approved","modality":"Small-molecule kinase inhibitor (BRAF)","route":"/drugs/encorafenib/"},{"id":"gc101-til","name":"GC101 TIL","status":"phase-2","modality":"TIL therapy","route":"/drugs/gc101-til/"},{"id":"guardant360-cdx","name":"Guardant360 CDx","status":"approved","modality":"Liquid biopsy companion diagnostic test (NGS, cfDNA)","route":"/drugs/guardant360-cdx/"},{"id":"oncomine-dx-target-test","name":"Oncomine Dx Target Test","status":"approved","modality":"Tissue NGS companion diagnostic test (multi-gene panel)","route":"/drugs/oncomine-dx-target-test/"},{"id":"sorafenib","name":"Sorafenib","status":"approved","modality":"Small-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)","route":"/drugs/sorafenib/"},{"id":"therascreen-cdx","name":"therascreen companion diagnostic kits (KRAS, EGFR, PIK3CA, FGFR, BRAF)","status":"approved","modality":"Real-time PCR companion diagnostic test family","route":"/drugs/therascreen-cdx/"},{"id":"tovorafenib","name":"Tovorafenib","status":"approved","modality":"Small-molecule type II RAF inhibitor","route":"/drugs/tovorafenib/"},{"id":"vemurafenib","name":"Vemurafenib","status":"approved","modality":"Small-molecule kinase inhibitor (BRAF V600)","route":"/drugs/vemurafenib/"}],"trials":[{"id":"nct04940052","name":"Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refracto","nct":"NCT04940052","phase":"3","status":"active"},{"id":"breakwater","name":"BREAKWATER","nct":"NCT04607421","phase":"3","status":"positive"},{"id":"nct03755791","name":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Rece","nct":"NCT03755791","phase":"3","status":"active"},{"id":"cairo5","name":"CAIRO5","nct":"NCT02162563","phase":"3","status":"mixed"},{"id":"dreamseq","name":"DREAMseq (ECOG-ACRIN EA6134)","nct":"NCT02224781","phase":"3","status":"positive"},{"id":"aaml1031","name":"AAML1031","nct":"NCT01371981","phase":"3","status":"mixed"},{"id":"imspire150","name":"IMspire150","nct":"NCT02908672","phase":"3","status":"positive"},{"id":"beacon-crc","name":"BEACON CRC","nct":"NCT02928224","phase":"3","status":"positive"},{"id":"imblaze370","name":"IMblaze370","nct":"NCT02788279","phase":"3","status":"negative"},{"id":"columbus","name":"COLUMBUS","nct":"NCT01909453","phase":"3","status":"positive"},{"id":"reflect","name":"REFLECT","nct":"NCT01761266","phase":"3","status":"positive"},{"id":"combi-ad","name":"COMBI-AD","nct":"NCT01682083","phase":"3","status":"positive"},{"id":"sarah-sirvenib","name":"SARAH and SIRveNIB","nct":"NCT01482442","phase":"3","status":"negative"},{"id":"cobrim","name":"coBRIM","nct":"NCT01689519","phase":"3","status":"positive"},{"id":"combi-d","name":"COMBI-d","nct":"NCT01584648","phase":"3","status":"positive"},{"id":"correct","name":"CORRECT","nct":"NCT01103323","phase":"3","status":"positive"},{"id":"decision-sorafenib","name":"DECISION","nct":"NCT00984282","phase":"3","status":"positive"},{"id":"lch-iii","name":"LCH-III","nct":"NCT00276757","phase":"3","status":"positive"},{"id":"prime","name":"PRIME","nct":"NCT00364013","phase":"3","status":"positive"},{"id":"sharp","name":"SHARP","nct":"NCT00105443","phase":"3","status":"positive"},{"id":"nct04657991","name":"A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma","nct":"NCT04657991","phase":"3","status":"active"},{"id":"nct05270044","name":"Adjuvant Encorafenib and Binimetinib in High-risk Stage II Melanoma With a BRAF Mutation.","nct":"NCT05270044","phase":"3","status":"active"},{"id":"nct05566795","name":"DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)","nct":"NCT05566795","phase":"3","status":"active"},{"id":"nct03803553","name":"Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer","nct":"NCT03803553","phase":"3","status":"active"},{"id":"safir-abc10","name":"SAFIR-ABC10","nct":"NCT05615818","phase":"3","status":"recruiting"},{"id":"orient-32","name":"ORIENT-32","nct":"NCT03794440","phase":"2/3","status":"positive"},{"id":"zgdh3","name":"ZGDH3 (donafenib vs sorafenib)","nct":"NCT02645981","phase":"2/3","status":"positive"},{"id":"nct05768178","name":"DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.","nct":"NCT05768178","phase":"2/3","status":"recruiting"},{"id":"nct07440290","name":"DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positi","nct":"NCT07440290","phase":"2/3","status":"recruiting"},{"id":"nct05710406","name":"Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer","nct":"NCT05710406","phase":"2/3","status":"active"},{"id":"pediatric-match","name":"NCI-COG Pediatric MATCH (APEC1621)","nct":"NCT03155620","phase":"platform","status":"active"},{"id":"nci-match","name":"NCI-MATCH (EAY131)","nct":"NCT02465060","phase":"platform","status":"active"},{"id":"determine-trial","name":"DETERMINE","nct":"NCT05722886","phase":"platform","status":"recruiting"},{"id":"nct04941287","name":"Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer","nct":"NCT04941287","phase":"2","status":"active"},{"id":"cupisco","name":"CUPISCO","nct":"NCT03498521","phase":"2","status":"positive"},{"id":"firefly-1","name":"FIREFLY-1","nct":"NCT04775485","phase":"2","status":"positive"},{"id":"pharos","name":"PHAROS","nct":"NCT03915951","phase":"2","status":"positive"},{"id":"tadpole","name":"TADPOLE (CDRB436G2201)","nct":"NCT02684058","phase":"2","status":"positive"},{"id":"chronos","name":"CHRONOS","nct":"NCT03227926","phase":"2","status":"positive"},{"id":"swog-s1406","name":"SWOG S1406","nct":"NCT02164916","phase":"2","status":"positive"},{"id":"roar","name":"ROAR (Rare Oncology Agnostic Research) basket: BRAF V600E biliary tract cancer cohort","nct":"NCT02034110","phase":"2","status":"positive"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"checkmate-142","name":"CheckMate 142","nct":"NCT02060188","phase":"2","status":"positive"},{"id":"mypathway","name":"MyPathway","nct":"NCT02091141","phase":"2","status":"completed"},{"id":"roar-atc","name":"ROAR (anaplastic thyroid cancer cohort)","nct":"NCT02034110","phase":"2","status":"positive"},{"id":"brf113928","name":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E)","nct":"NCT01336634","phase":"2","status":"positive"},{"id":"opus","name":"OPUS","nct":"NCT00125034","phase":"2","status":"positive"},{"id":"nct00943449","name":"4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma","nct":"NCT00943449","phase":"2","status":"completed"},{"id":"nct07560111","name":"A Phase II Study of GC101 in NSCLC","nct":"NCT07560111","phase":"2","status":"recruiting"},{"id":"nct07506109","name":"A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colo","nct":"NCT07506109","phase":"2","status":"recruiting"},{"id":"nct02050321","name":"A Phase II Study of Vemurafenib Combined With Acitretin in Patients With Advanced Melanoma","nct":"NCT02050321","phase":"2"},{"id":"nct04931342","name":"A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors","nct":"NCT04931342","phase":"2","status":"active"},{"id":"nct05217446","name":"A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic","nct":"NCT05217446","phase":"2","status":"active"},{"id":"nct06703398","name":"A Study of GC101 TIL in Advanced Melanoma","nct":"NCT06703398","phase":"2","status":"recruiting"},{"id":"nct04302025","name":"A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)","nct":"NCT04302025","phase":"2","status":"recruiting"},{"id":"nct05503797","name":"A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations","nct":"NCT05503797","phase":"2","status":"recruiting"},{"id":"nct07178717","name":"A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy W","nct":"NCT07178717","phase":"2","status":"planned"},{"id":"nct07449754","name":"Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma","nct":"NCT07449754","phase":"2","status":"recruiting"},{"id":"nct06411600","name":"Combination Therapy for BRAF-V600E Metastatic CRCm","nct":"NCT06411600","phase":"2","status":"recruiting"},{"id":"combomatch-binimetinib-folfox","name":"ComboMATCH: FOLFOX with or without binimetinib in second-line biliary tract cancer with MAPK pathway alterations","nct":"NCT05564403","phase":"2","status":"active"},{"id":"nct07787429","name":"Evaluation of the Safety and Efficacy of Mifamurtide Versus Standard Treatment With Sorafenib in Patients With High-risk Osteosarcoma","nct":"NCT07787429","phase":"2","status":"recruiting"},{"id":"nct05195632","name":"Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung","nct":"NCT05195632","phase":"2","status":"active"},{"id":"nct05822752","name":"Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu","nct":"NCT05822752","phase":"2","status":"active"},{"id":"nct05725200","name":"Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer","nct":"NCT05725200","phase":"2","status":"recruiting"},{"id":"nct06813079","name":"Using Tumor Models to Determine Treatments","nct":"NCT06813079","phase":"2","status":"recruiting"},{"id":"nct05585320","name":"A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors","nct":"NCT05585320","phase":"1/2","status":"active"},{"id":"nct07617805","name":"EGFR/HER2 Dual-Target CAR-NK Cells for Recurrent or Metastatic HNSCC","nct":"NCT07617805","phase":"1/2","status":"recruiting"},{"id":"nct03947385","name":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","nct":"NCT03947385","phase":"1/2","status":"recruiting"}],"pathways":["colorectal-cancer-signalling","glioma-signalling","melanoma-signalling","pancreatic-cancer-signalling","ras-mapk","thyroid-cancer-signalling"],"companies":["bayer","black-diamond-therapeutics","day-one-biopharmaceuticals","guardant-health","imagene-ai","ipsen","natco","nested-therapeutics","novartis","pfizer","pierre-fabre","qiagen","roche-genentech","shanghai-juncell-therapeutics","zelgen","thermo-fisher"],"keyPapers":["paper-breakwater-nejm-2025","paper-philip-kras-wild-type-pancreatic-ccr-2022","paper-mody-biliary-ctdna-profiling-jco-po-2019","paper-aggarwal-plasma-genotyping-personalised-therapy-jama-oncol-2019","paper-kopetz-beacon-encorafenib-braf-colorectal-nejm-2019","paper-leighl-nile-cfdna-tissue-genotyping-ccr-2019","paper-crockett-nagtegaal-serrated-neoplasia-gastroenterology-2019","paper-loree-tumour-location-continuum-colorectal-ccr-2018","paper-yaeger-metastatic-colorectal-genomic-landscape-cancer-cell-2018","paper-aguirre-real-time-genomic-characterisation-pancreatic-cancer-discov-2018","paper-lindeman-lung-molecular-testing-guideline-jto-2018","paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","paper-jones-non-v600-braf-colorectal-jco-2017","paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","paper-tracerx-100-nejm-2017","paper-giannakis-genomic-correlates-immune-colorectal-cell-rep-2016","paper-richman-her2-amplification-quasar-focus-piccolo-j-pathol-2016","paper-cremolini-tribe-folfoxiri-bevacizumab-lancet-oncol-2015","paper-cms-guinney-nat-med-2015","paper-witkiewicz-pancreatic-exomes-utsw-nat-commun-2015","paper-missiaglia-distal-proximal-colon-cancers-ann-oncol-2014","paper-venderbosch-mmr-braf-metastatic-colorectal-pooled-ccr-2014","paper-kris-lung-cancer-mutation-consortium-jama-2014","paper-vogelstein-cancer-genome-landscapes-science-2013","paper-douillard-prime-panitumumab-ras-nejm-2013","paper-bettington-serrated-pathway-colorectal-histopathology-2013","paper-kanda-panin-1-somatic-mutations-gastroenterology-2012","paper-weisenberger-cimp-braf-mlh1-colorectal-nat-genet-2006"],"hotspots":[{"label":"V600E","position":600,"kind":"activating","frequency":"About half of cutaneous melanomas; 8 to 12% of colorectal cancers; nearly all hairy cell leukaemias","drugs":["dabrafenib-trametinib","encorafenib","vemurafenib","binimetinib","cobimetinib","tovorafenib"]},{"label":"V600K","position":600,"kind":"activating","frequency":"About 10 to 20% of BRAF V600 melanoma","drugs":["dabrafenib-trametinib","encorafenib","vemurafenib"]},{"label":"Class II (K601E, G469A/V, L597, fusions)","position":469,"kind":"activating","drugs":["tovorafenib"]},{"label":"Class III (D594, G466, N581)","position":594,"kind":"other","drugs":[]}],"openQuestions":[{"id":"braf-crc-first-line","question":"Does BREAKWATER's first-line encorafenib plus cetuximab plus chemotherapy improve overall survival enough to displace chemotherapy plus bevacizumab for every BRAF V600E colorectal patient?","stage":"clinical","actor":"clinic","source":{"label":"BREAKWATER (ClinicalTrials.gov)","url":"https://clinicaltrials.gov/study/NCT04607421"}}],"assays":[{"id":"braf-cobas","name":"cobas 4800 BRAF V600 Mutation Test","cutoff":"V600 mutation detected"},{"id":"braf-thxid","name":"THxID BRAF Kit","cutoff":"V600E or V600K detected"},{"id":"braf-therascreen","name":"therascreen BRAF V600E RGQ PCR Kit","cutoff":"V600E detected (colorectal cancer, encorafenib plus cetuximab)"},{"id":"foundationone-cdx-panel","name":"FoundationOne CDx","cutoff":"Per companion claim: EGFR, ALK, BRAF V600, ERBB2 amplification, KRAS wild-type, BRCA1/2 and HRR genes, PIK3CA, MET exon 14, RET, FGFR2 fusions, IDH1, NTRK fusions; MSI-high; TMB at least 10 mutations per megabase"},{"id":"oncomine-dx","name":"Oncomine Dx Target Test","cutoff":"Per companion claim: BRAF V600E (dabrafenib plus trametinib), ROS1 fusions (crizotinib), EGFR (gefitinib), RET fusions (pralsetinib), MET exon 14 (tepotinib), EGFR exon 20 insertions"}],"resistance":[{"class":"kras-g12c","mechanism":"Bypass alterations (MET amplification, NRAS/BRAF mutations, RTK fusions)","category":"bypass"}],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}